Información de Genmab A/S, dividendo de Genmab A/S, actividades de los accionistas y más

Más Datos de Genmab A/S Compañía

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Información de Genmab A/S



Símbolo de cotizaciónGMAB

Nombre de la empresaGenmab A/S

Fecha de salida a bolsaOct 01, 2000

Director ejecutivoDr. Jan G.J. Van De Winkel, Ph.D.

Número de empleados2682

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 01

DirecciónCarl Jacobsens Vej 30

CiudadVALBY

Bolsa de valoresOMX Nordic Exchange Copenhagen A/S

PaísDenmark

Código postal2500

Teléfono4570202728

Sitio Webhttps://www.genmab.com/

Símbolo de cotizaciónGMAB

Fecha de salida a bolsaOct 01, 2000

Director ejecutivoDr. Jan G.J. Van De Winkel, Ph.D.

Ejecutivos de Genmab A/S



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Mr. Christopher Cozic

Executive Vice President, Chief People Officer

--

Mr. Martin Schultz

Non-Independent Director, Employee Elected

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

Dr. Paolo Paoletti, M.D.

Independent Director

--

Dr. Jan G.J. Van De Winkel, Ph.D.

President, Chief Executive Officer

--

Ms. Mijke Zachariasse, Ph.D.

Non-Independent Director, Employee Elected

--

Ms. Elizabeth A. O'farrell

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Mr. Christopher Cozic

Executive Vice President, Chief People Officer

--

Mr. Martin Schultz

Non-Independent Director, Employee Elected

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Royalties

789.00M

85.30%

Net product sales

101.00M

10.92%

Collaboration revenue

21.00M

2.27%

Reimbursement income

13.00M

1.41%

Milestone payments

1.00M

0.11%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Royalties

789.00M

85.30%

Net product sales

101.00M

10.92%

Collaboration revenue

21.00M

2.27%

Reimbursement income

13.00M

1.41%

Milestone payments

1.00M

0.11%

Estadísticas de accionistas

Actualizado: sáb., 8 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

AllianceBernstein L.P.

1.73%

Orbis Investment Management Ltd.

1.29%

Citadel Advisors LLC

0.58%

Arrowstreet Capital, Limited Partnership

0.56%

Two Sigma Investments, LP

0.56%

Otro

95.28%

Accionistas

Proporción

AllianceBernstein L.P.

1.73%

Orbis Investment Management Ltd.

1.29%

Citadel Advisors LLC

0.58%

Arrowstreet Capital, Limited Partnership

0.56%

Two Sigma Investments, LP

0.56%

Otro

95.28%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

4.32%

Investment Advisor

3.18%

Hedge Fund

2.35%

Research Firm

0.64%

Pension Fund

0.03%

Bank and Trust

0.02%

Family Office

0.01%

Otro

89.45%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

515

64.81M

10.54%

-15.68M

2025Q2

501

65.30M

10.31%

-6.21M

2025Q1

515

65.99M

10.42%

-5.32M

2024Q4

512

61.76M

9.33%

+621.44K

2024Q3

493

53.46M

8.41%

-4.14M

2024Q2

495

49.90M

7.86%

-6.30M

2024Q1

501

49.04M

7.53%

-7.16M

2023Q4

490

47.86M

7.32%

-6.37M

2023Q3

479

48.54M

7.43%

+204.98K

2023Q2

467

42.76M

6.55%

-5.77M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

AllianceBernstein L.P.

10.66M

1.73%

-4.06M

-27.59%

Jun 30, 2025

Orbis Investment Management Ltd.

7.92M

1.29%

+2.21M

+38.69%

Jun 30, 2025

Citadel Advisors LLC

3.57M

0.58%

-857.47K

-19.37%

Jun 30, 2025

Arrowstreet Capital, Limited Partnership

3.45M

0.56%

+2.08M

+152.25%

Jun 30, 2025

Two Sigma Investments, LP

3.44M

0.56%

-433.92K

-11.20%

Jun 30, 2025

Harding Loevner LP

2.92M

0.48%

+42.61K

+1.48%

Jun 30, 2025

Renaissance Technologies LLC

2.77M

0.45%

+504.40K

+22.30%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.50M

0.41%

-443.29K

-15.04%

Jun 30, 2025

Marshall Wace LLP

1.91M

0.31%

-274.23K

-12.57%

Jun 30, 2025

First Trust Advisors L.P.

1.77M

0.29%

+60.50K

+3.54%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Tema Oncology ETF

5.08%

First Trust NYSE Arca Biotechnology Index Fund

4.45%

WisdomTree BioRevolution Fund

1.33%

iShares Biotechnology ETF

1.32%

AB Disruptors ETF

0.92%

First Trust NASDAQ BuyWrite Income ETF

0.29%

ProShares Ultra Nasdaq Biotechnology

0.13%

Invesco Nasdaq Biotechnology ETF

0.13%

ActivePassive International Equity ETF

0.13%

Avantis International Equity ETF

0.1%

Tema Oncology ETF

Proporción5.08%

First Trust NYSE Arca Biotechnology Index Fund

Proporción4.45%

WisdomTree BioRevolution Fund

Proporción1.33%

iShares Biotechnology ETF

Proporción1.32%

AB Disruptors ETF

Proporción0.92%

First Trust NASDAQ BuyWrite Income ETF

Proporción0.29%

ProShares Ultra Nasdaq Biotechnology

Proporción0.13%

Invesco Nasdaq Biotechnology ETF

Proporción0.13%

ActivePassive International Equity ETF

Proporción0.13%

Avantis International Equity ETF

Proporción0.1%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos